In vitro metabolism of a novel PPARγ agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s

Xenobiotica

Volumn 38, Issue 9, 2008, Pages 1165-1176

  Kim, K B ^a   Seo, K A ^a   Yoon, Y J ^a   Bae, M A ^b   Cheon, H G ^b   Shin, J G ^a,c   Liu, K H ^a,d  

^a Inje University College of Medicine   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Inje University   (South Korea)

Author keywords

CYP1A2; CYP2D6; CYP3A4; CYP3A5; KR 62980; KR 63198; Liquid chromatography tandem mass spectrometry (LC MS MS); Metabolism; Microsomes

Indexed keywords

1 (METHYLIMINO N OXY) 6 (2 MORPHOLINOETHYOXY) 3 PHENYL 1H INDENE 2 CARBOXYLIC ACID ETHYL ESTER; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; KR 62980; KR 63198; NICOTINAMIDE ADENINE DINUCLEOTIDE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; STEREOCHEMISTRY; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INDENES; KINETICS; MASS SPECTROMETRY; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MORPHOLINES; PPAR GAMMA; RECOMBINANT PROTEINS;

EID: 50249111587     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802037309     Document Type: Article

References (22)

1. Agranat I, Caner H, Caldwell J. 2002. Putting chirality to work: The strategy of chiral switches. Nature Reviews in Drug Discovery 1:753-768.
2. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. 2001. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clinical Pharmacokinetics 40:411-426.
3. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
4. Berger JP, Petro AE, MacNaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, et al. 2003. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Molecular Endocrinology 17:662-676.
5. Bourrie M, Meunier V, Berger Y, Fabre G. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 277:321-332.
6. Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B. 1989. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. British Journal of Clinical Pharmacology 28:29-36.
7. Caner H, Groner E, Levy L, Agranat I. 2004. Trends in the development of chiral drugs. Drug Discovery Today 9:105-110.
8. Gross AS, Eichelbaum M, Morike K, Mikus G. 2000. Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. British Journal of Clinical Pharmacology 49:132-138.
9. Kim JY, Baek M, Lee S, Kim SO, Dong MS, Kim BR, Kim DH. 2001. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl- 2,2′-dicarboxylate. Drug Metabolism and Disposition: The Biological Fate of Chemicals 29:1555-1560.
10. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. 2003. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 31:1227-1234.
11. Kim KR, Lee JH, Kim SJ, Rhee SD, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG. 2006. KR-62980: A novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. Biochemical Pharmacology 72:446-454.
12. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. 2005. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 19:2651-2658.
13. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. 2002. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 30:1108-1114.
14. Misra P, Chakrabarti R, Vikramadithyan RK, Bolusu G, Juluri S, Hiriyan J, Gershome C, Rajjak A, Kashireddy P, Yu S, et al. 2003. PAT5A: A partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. Journal of Pharmacology and Experimental Therapeutics 306:763-771.
15. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, et al. 1999. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proceedings of the National Academy of Sciences of the USA 96:6102-6106.
16. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, et al. 2001. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Molecular Cell 8:737-747.
17. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS. 1990. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 29:651-663.
18. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414-423.
19. Streetman DS, Bertino Jr JS, Nafziger AN. 2000. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216.
20. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. 1990. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology 38:207-213.
21. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. 2004. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
22. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes 50:411-417.